Some studies have found a correlation between intravitreal anti-VEGF therapy for neovascular AMD and an increased risk of developing GA [176,177,178,179], but it is unclear if this is due to common advanced AMD processes or if VEGF inhibition leads to retinal cell damage related to complement. The gene discussed is VEGFA; the disease is age-related macular degeneration.